Leading
the way.
Testing developed
by neurologists for neurologists.
Neurology testing is rapidly evolving with increasing numbers of clinically relevant biomarkers discovered each year. Our laboratory collaborates closely with the practice and is designed to offer the most complex, clinically validated testing. Our disease experts support health care professionals in test selection and result interpretation to ensure proper test utilization and the highest quality of care. These physicians are committed to research and discovery to pave the way for the future of neurology testing.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly neurology newsletter.
Results That Matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
400+
laboratory tests developed for our specialized neurology test menu
169
neurologists on staff at Mayo Clinic
19
testing laboratories performing
neurology testing
24/7
support from Mayo Clinic physicians and scientists
Advancing the
science
Novel biomarker discoveries occur at a rapid pace, and we are at the forefront of research that integrates these findings into our testing. We were the first laboratory to develop disease-specific evaluations, and our patient-care experience gives us the expertise to develop tests that deliver clinically relevant answers.
The largest neurology-specific test menu
Our highly specialized test menu provides answers for everything from the simplest to the most complex cases—and much of this testing is not available anywhere else.
Access to Mayo Clinic expertise
Our laboratories are led by clinical neurologists who have extensive experience in using testing to guide and directly impact patient care. These experts interpret each evaluation, providing clinically actionable answers, not just results.
New Testing for
Diagnosing Autoimmune Stiff-Person Syndrome
Mayo Clinic Laboratories launched glycine receptor antibody testing to complement antibody evaluations of GAD65-IgG and existing movement disorder panels to add to the overall accuracy of a diagnosis of autoimmune stiff-person syndrome.
The Latest
PACE
This “Specialty Testing” webinar will address the clinical presentations, evaluation (including diagnostic antibody testing), and treatment of autoimmune pediatric CNS disorders, including encephalitides and myelopathies.
Currently the diagnosis of probable Alzheimer disease (AD) is made based on clinical symptoms, largely by the exclusion of other causes of dementia, with postmortem evidence of AD pathology required to confirm the diagnosis. Two common neuropathologic features found in the brains of patients with AD are the presence of plaques composed of beta-amyloid (Abeta) peptides and intracellular neurofibrillary tangles containing hyperphosphorylated Tau (tubulin-associated unit) proteins.
Divyanshu Dubey, M.B.B.S. gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
Autoimmune encephalitis and myelitis is increasingly recognized as a cause of CNS disease in children and teens. Andrew McKeon, M.B., B.Ch., M.D, gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
In this month’s “Hot Topic,” Divyanshu Dubey, M.B.B.S., discusses how patients with encephalopathy and/or epilepsy of unknown etiology may have an autoimmune or paraneoplastic cause.